Jeffrey A. Moscow, MD, joined the Investigational Drug Branch in January, 2014, after serving part-time in IDB since August, 2012. Prior to joining CTEP, he was Children’s Miracle Network Professor of Pediatrics, Chief of Pediatric Hematology-Oncology, Vice Chair of Pediatrics, and co-leader of the Experimental Therapeutics Program of the Markey Cancer Center, all at the University of Kentucky. His portfolio includes erlotinib, lapatanib, AZD 9291, CO-1686, trebananib, ch14.18, and CDX-011. Dr. Moscow has also taken a lead role in the re-design of the CTEP Phase 2 component of the Early Therapeutics Clinical Trials Network (ETCTN) and is slated to become its program director. In addition, Dr. Moscow has a laboratory research program in the Urologic Oncology Branch that is focused on targeting thiamine-dependent enzymes for cancer therapy.
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850